Active Not Recruiting PHASE1 INTERVENTIONAL 4-arm NCT04848272

Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

Sponsor: St Vincent's Institute of Medical Research

Interventions Lanadelumab Saline control

Updated 5 times since 2021 Last updated: Apr 15, 2024 Started: Aug 9, 2021 Primary completion: Dec 31, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04848272, this PHASE1 trial focuses on Lung Injury and remains ongoing. Sponsored by St Vincent's Institute of Medical Research, it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jun 2022 — May 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
May 2021 — Jun 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

St Vincent's Institute of Medical Research

Data source: St Vincent's Institute of Medical Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia